CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 99 enrolled
Drug / intervention
RN624 +2 moredrug
Likely dose
RN624 50 mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00568321
NCT00568321Phase 2Completed
CompareCT.gov

A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL GROUP, PROOF OF CONCEPT STUDY OF THE ANALGESIC EFFECTS OF RN624 IN ADULT PATIENTS WITH POST-HERPETIC NEURALGIA

Pfizer·interventional·Posted Dec 6, 2007·Updated May 28, 2021

In Brief

A Phase 2 clinical trial evaluating RN624 and Placebo for Neuralgia, Postherpetic. Completed, enrolled 99 participants across 31 sites.

Detailed Summary

This study will test the efficacy and safety of two doses levels of RN624 versus placebo for the relief of pain caused by post-herpetic neuralgia (PHN).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuralgia, Postherpetic
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 6, 2007
Enrollment StartDec 19, 2007
Primary CompletionDec 20, 2008
Study CompletionJan 7, 2009
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 18.6 years ago

Interventions

RN624drug

50 mcg/kg

RN624drug

200 mcg/kg

Placebodrug

placebo